Superworth

Xenon Pharmaceuticals price to book ratio XENE

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
2.8×
10-year median
3.2×
Against its 10-year history
32nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.0× to 8.5×
Peer median
6.3×

Xenon Pharmaceuticals' price to book ratio is 2.8× as of Oct 23, 2026.

That is below its ten-year median of 3.2×, lower than on 68% of days in the last ten years.

Over that time it ranged from 1.0× in Nov 2017 to 8.5× in Apr 2026.

The median for 10 large drugmakers of a similar size is 6.3×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.8×2.6×8.5×
20256.2×3.0×6.2×
20243.7×3.1×5.1×
20234.7×2.9×4.7×
20223.3×2.6×6.6×
20216.5×2.4×6.5×
20203.0×1.8×6.0×
20194.6×1.6×4.8×
20181.3×1.2×5.4×
20171.2×1.0×2.3×
20162.0×1.5×2.3×
20151.8×1.7×3.6×

Against its peers

Companies in Drug Manufacturers - General nearest Xenon Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
XENEXenon Pharmaceuticals2.8×
OGNOrganon3.6×
LQDALiquidia19.6×
ARQTArcutis Biotherapeutics17.8×
INDVIndivior Pharmaceuticalsn/m
NRIXNurix Therapeutics2.9×
PBHPrestige Consumer Healthcare1.2×
HRMYHarmony Biosciences2.1×
KNSAKiniksa Pharmaceuticals International9.2×
LGNDLigand Pharmaceuticals6.3×
AMRXAmneal Pharmaceuticals197×
Peer median6.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Xenon Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.